Compare MG & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MG | ZURA |
|---|---|---|
| Founded | 1978 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.4M | 252.9M |
| IPO Year | 2009 | N/A |
| Metric | MG | ZURA |
|---|---|---|
| Price | $12.70 | $4.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 197.8K | ★ 369.0K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.33 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $715,300,000.00 | N/A |
| Revenue This Year | $1.46 | N/A |
| Revenue Next Year | $3.61 | N/A |
| P/E Ratio | $22.46 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.06 | $0.97 |
| 52 Week High | $13.43 | $4.68 |
| Indicator | MG | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 61.74 | 62.87 |
| Support Level | $12.20 | $3.88 |
| Resistance Level | $13.05 | $4.45 |
| Average True Range (ATR) | 0.49 | 0.25 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 83.15 | 79.37 |
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.